Trials / Withdrawn
WithdrawnNCT00878748
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
An Open Label, Prospective and Multi-center Recurrence Prevention Study With Effexor XR in MDD Patients in China
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an 8-week acute treatment and a 6-month continuation treatment phases. The study will also collect data on the prevalence and pattern of co-morbid anxiety and somatic symptoms and their impact on the recurrence of depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Effexor XR | |
| OTHER | Effexor XR discontinue |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2009-04-09
- Last updated
- 2021-08-20
Source: ClinicalTrials.gov record NCT00878748. Inclusion in this directory is not an endorsement.